Related references
Note: Only part of the references are listed.Evaluation of Bayesian Forecasting Methods for Prediction of Tacrolimus Exposure Using Samples Taken on Two Occasions in Adult Kidney Transplant Recipients
Emily Brooks et al.
THERAPEUTIC DRUG MONITORING (2021)
Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients
Rachael Lawson et al.
CLINICAL PHARMACOKINETICS (2021)
Limited Sampling Strategies Supporting Individualized Dose Adjustment of Intravenous Busulfan in Children and Young Adults
Zvi Teitelbaum et al.
THERAPEUTIC DRUG MONITORING (2020)
Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation
Brian T. Hill et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Population pharmacokinetic analysis of intravenous busulfan: GSTA1 genotype is not a predictive factor of initial dose in Chinese adult patients undergoing hematopoietic stem cell transplantation
Yidan Sun et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)
Busulfan systemic exposure and its relationship with efficacy and safety in hematopoietic stem cell transplantation in children: a meta-analysis
Xinying Feng et al.
BMC PEDIATRICS (2020)
Intra-individual Pharmacokinetic Variability of Intravenous Busulfan in Hematopoietic Stem Cell-Transplanted Children
Hanen Marsit et al.
CLINICAL PHARMACOKINETICS (2020)
Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand
Piyawat Chaivichacharn et al.
CLINICAL THERAPEUTICS (2020)
Software Tools for Model-Informed Precision Dosing: How Well Do They Satisfy the Needs?
Wannee Kantasiripitak et al.
FRONTIERS IN PHARMACOLOGY (2020)
Model-Informed Precision Dosing of Vancomycin in Hospitalized Children: Implementation and Adoption at an Academic Children's Hospital
Adam Frymoyer et al.
FRONTIERS IN PHARMACOLOGY (2020)
Assessment of a Model-Informed Precision Dosing Platform Use in Routine Clinical Care for Personalized Busulfan Therapy in the Pediatric Hematopoietic Cell Transplantation (HCT) Population
Praveen Shukla et al.
FRONTIERS IN PHARMACOLOGY (2020)
Optimizing Predictive Performance of Bayesian Forecasting for Vancomycin Concentration in Intensive Care Patients
Tingjie Guo et al.
PHARMACEUTICAL RESEARCH (2020)
Usefulness of population pharmacokinetics to optimize the dosage regimen of infliximab in inflammatory bowel disease patients
Mayte Gil Candel et al.
REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS (2020)
Evaluation of a Test Dose Strategy for Pharmacokinetically-Guided Busulfan Dosing for Hematopoietic Stem Cell Transplantation
Jessica M. Davis et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Personalized pharmacokinetic targeting with busulfan in allogeneic hematopoietic stem cell transplantation in infants with acute lymphoblastic leukemia
Takayuki Takachi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2019)
Systematic external evaluation of published population pharmacokinetic models of mycophenolate mofetil in adult kidney transplant recipients co-administered with tacrolimus
Huan-Xi Zhang et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Accurate Prediction of Initial Busulfan Exposure Using a Test Dose With 2-and 6-Hour Blood Sampling in Adult Patients Receiving a Twice-Daily Intravenous Busulfan-Based Conditioning Regimen
Jingjing Huang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies
Manar M. Khalil et al.
ANNALS OF HEMATOLOGY (2018)
Busulfan, Fludarabine, and Cyclophosphamide (BFC) conditioning allowed stable engraftment after haplo-identical allogeneic stem cell transplantation in children with adrenoleukodystrophy and mucopolysaccharidosis
Yao Chen et al.
BONE MARROW TRANSPLANTATION (2018)
Is pharmacokinetic guidance a must in busulfan regimens?
Yoshinobu Kanda
LANCET HAEMATOLOGY (2018)
External evaluation of population pharmacokinetic models for ciclosporin in adult renal transplant recipients
Jun-Jun Mao et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
A Significant Influence of Metronidazole on Busulfan Pharmacokinetics: A Case Report of Therapeutic Drug Monitoring
Hyewon Chung et al.
THERAPEUTIC DRUG MONITORING (2017)
Limited sampling strategy for predicting busulfan exposure in hematopoietic stem cell transplantation recipients
Jing-jing Huang et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY (2017)
Tools for the Individualized Therapy of Teicoplanin for Neonates and Children
V. Ramos-Martin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Population pharmacokinetics analysis of intravenous busulfan in Chinese patients undergoing hematopoietic stem cell transplantation
Xuemei Wu et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2017)
Should busulfan therapeutic range be narrowed in pediatrics? Experience from a large cohort of hematopoietic stem cell transplant children
M. Philippe et al.
BONE MARROW TRANSPLANTATION (2016)
Influence of glutathione S-transferase gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem-cell transplantation in thalassemia pediatric patients
M. Ansari et al.
BONE MARROW TRANSPLANTATION (2016)
Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee
Jeanne Palmer et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients
Chen-Yan Zhao et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?
Emily Brooks et al.
CLINICAL PHARMACOKINETICS (2016)
Clinical Decision Support Tools: The Evolution of a Revolution
D. R. Mould et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
Once-daily i.v. BU-based conditioning regimen before allogeneic hematopoietic SCT: a study of influence of GST gene polymorphisms on BU pharmacokinetics and clinical outcomes in Chinese patients
J. Yin et al.
BONE MARROW TRANSPLANTATION (2015)
Dosing algorithm revisit for busulfan following IV infusion
Yanlin Wang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation
Boyoon Choi et al.
PHARMACOGENOMICS (2015)
Population Pharmacokinetics of Busulfan in Pediatric and Young Adult Patients Undergoing Hematopoietic Cell Transplant: A Model-Based Dosing Algorithm for Personalized Therapy and Implementation Into Routine Clinical Use
Janel R. Long-Boyle et al.
THERAPEUTIC DRUG MONITORING (2015)
Supporting data for characterization of the busulfan metabolite EdAG and the Glutaredoxins that it adducts
Michele Scian et al.
DATA IN BRIEF (2015)
Individualization of Piperacillin Dosing for Critically Ill Patients: Dosing Software To Optimize Antimicrobial Therapy
T. W. Felton et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Conditioning Chemotherapy Dose Adjustment in Obese Patients: A Review and Position Statement by the American Society for Blood and Marrow Transplantation Practice Guideline Committee
Joseph Bubalo et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103)
Jan H. Beumer et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Busulfan in Infant to Adult Hematopoietic Cell Transplant Recipients: A Population Pharmacokinetic Model for Initial and Bayesian Dose Personalization
Jeannine S. McCune et al.
CLINICAL CANCER RESEARCH (2014)
Review of therapeutic drug monitoring of anticancer drugs part 1-Cytotoxics
Angelo Paci et al.
EUROPEAN JOURNAL OF CANCER (2014)
Glutathione S-transferase gene variations influence BU pharmacokinetics and outcome of hematopoietic SCT in pediatric patients
M. Ansari et al.
BONE MARROW TRANSPLANTATION (2013)
Predictive performance of reported population pharmacokinetic models of vancomycin in Chinese adult patients
C. Deng et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2013)
Association Between Busulfan Exposure and Outcome in Children Receiving Intravenous Busulfan Before Hematopoietic Stem Cell Transplantation
Marc Ansari et al.
THERAPEUTIC DRUG MONITORING (2013)
Accurate Targeting of Daily Intravenous Busulfan with 8-Hour Blood Sampling in Hospitalized Adult Hematopoietic Cell Transplant Recipients
Rosa F. Yeh et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Development and Validation of a Test Dose Strategy for Once-Daily i.v. Busulfan: Importance of Fixed Infusion Rate Dosing
S. Bill Kangarloo et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Deferasirox increases BU blood concentrations
K. Sweiss et al.
BONE MARROW TRANSPLANTATION (2012)
Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial
G. J. Veal et al.
EUROPEAN JOURNAL OF CANCER (2012)
A Simple Dosing Scheme for Intravenous Busulfan Based on Retrospective Population Pharmacokinetic Analysis in Korean Patients
Sangmin Choe et al.
KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY (2012)
Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models
Martin Bergstrand et al.
AAPS JOURNAL (2011)
Busulfan and Metronidazole: An Often Forgotten but Significant Drug Interaction
Alison M Gulbis et al.
ANNALS OF PHARMACOTHERAPY (2011)
Population Pharmacokinetics of Busulfan in Children: Increased Evidence for Body Surface Area and Allometric Body Weight Dosing of Busulfan in Children
Mirjam N. Trame et al.
CLINICAL CANCER RESEARCH (2011)
Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients
Reta Malaer et al.
PEDIATRIC TRANSPLANTATION (2011)
Influence of GST gene polymorphisms on busulfan pharmacokinetics in children
M. Ansari et al.
BONE MARROW TRANSPLANTATION (2010)
Development of a Population Pharmacokinetics-Based Sampling Schedule to Target Daily Intravenous Busulfan for Outpatient Clinic Administration
David H. Salinger et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Association between Busulfan Exposure and Outcome in Children Receiving Intravenous Busulfan before Hematologic Stem Cell Transplantation
Imke H. Bartelink et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Developmental Changes in Hepatic Antioxidant Capacity Are Age- and Sex-Dependent
Shogo J. Miyagi et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2009)
Glutathione S-transferase Polymorphisms Are Not Associated With Population Pharmacokinetic Parameters of Busulfan in Pediatric Patients
Juliette Zwaveling et al.
THERAPEUTIC DRUG MONITORING (2009)
Mechanism-based concepts of size and maturity in pharmacokinetics
B. J. Anderson et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2008)
Integration of modeling and simulation into hospital-based decision support systems guiding pediatric pharmacotherapy
Jeffrey S. Barrett et al.
BMC MEDICAL INFORMATICS AND DECISION MAKING (2008)
Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation
H Takama et al.
BONE MARROW TRANSPLANTATION (2006)
Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study
L Nguyen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
M de Lima et al.
BLOOD (2004)
I. V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients
L Nguyen et al.
BONE MARROW TRANSPLANTATION (2004)
Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: Study of pharmacokinetics and early clinical outcomes
JA Russell et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2002)
Share Paper
